Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | F13A1 | P00488 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | TGM1 | P22735 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621378 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL70762 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2621382 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2621342 | 0.94 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2621369 | 0.94 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2999166 | 0.94 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5747781 | 0.91 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5747776 | 0.91 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5747789 | 0.91 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL603957 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202760-B1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-9999673-B2 | PEGylated lipids and their use for drug delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-05-10 | — | — | US | disclosed |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
| US-20180037893-A1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-9796977-B2 | Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796977-B2 | Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9771345-B2 | Coferons and methods of making and using them | CORNELL UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771345-B2 | Coferons and methods of making and using them | CORNELL UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-5658928-A | ANTICOAGULANTS, ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENTS,WOUND HEALING AGENTS, OSTEOPOROSIS | HOFFMANN-LA ROCHE INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5571909-A | ANTIBIOTICS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1996-11-05 | — | — | US | disclosed |
| US-5545658-A | FOR TREATMENT OR PROPHYLAXIS OF ILLNESSES WHICH ARE CAUSED BY THE BINDING OF ADHESIVE PROTEINS TO BLOOD PLATELETS AND BY BLOOD PLATELET AGGREGATION AND CELL-CELL ADHESION | HOFFMAN-LA ROCHE INC. (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0505868-B1 | N-Acyl-alpha-aminoacids derivatives | HOFFMANN LA ROCHE (CH) | 1995-09-13 | — | — | EP | disclosed |
| US-5378712-A | Antithrombosis | Hoffmann-La Roche Inc (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0505868-A2 | N-Acyl-alpha-aminoacids derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-09-30 | — | — | EP | disclosed |
| EP-0416393-A1 | Peptidyl difluorodiol renin inhibitors | ABBOTT LABORATORIES (US) | 1991-03-13 | — | — | EP | disclosed |
| WO-1989010751-A1 | FUNCTIONALIZED PEPTIDYL AMINODIOLS AND -TRIOLS | ABBOTT LABORATORIES (US) | 1989-11-16 | — | — | WO | disclosed |
| EP-0341602-A2 | Renin-inhibiting functionalized peptidyl aminodiols and - triols | ABBOTT LABORATORIES (US) | 1989-11-15 | — | — | EP | disclosed |
| EP-0307837-A2 | Renin-inhibiting peptidyl heterocycles | ABBOTT LABORATORIES (US) | 1989-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | SMN1; SMN2 1515/4885NPC1 10/4885RAB9A 1625/4885 |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | SMN1; SMN2 1568/4885NPC1 13/4885RAB9A 1706/4885 |
| US-20180037893-A1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | SMN1; SMN2 4302/4885NPC1 16/4885RAB9A 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.